Seres Therapeutics Inc (NAS:MCRB)
$ 0.7589 -0.017 (-2.19%) Market Cap: 114.94 Mil Enterprise Value: 221.66 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 49/100

Seres Therapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript

Jun 09, 2020 / 06:10PM GMT
Release Date Price: $4.65 (-3.12%)
Terence C. Flynn
Goldman Sachs Group, Inc., Research Division - MD

Great. Good afternoon, everybody. Thank you for joining us. I'm Terence Flynn, the biopharma analyst at Goldman Sachs, and we're very pleased to have Seres Therapeutics with us. Today from the company we have Eric Shaff, President and CEO; Matt Henn, Chief Scientific Officer; and Lisa von Moltke, who's Chief Medical Officer. Thank you all for joining us. Really appreciate your time today.

Maybe just to get started, was wondering if you could just give a brief overview of the company and the current development programs for those of us that aren't as familiar with the company.

Eric D. Shaff
Seres Therapeutics, Inc. - President, CEO & Director

Sure, Terence, and thank you, again, for having us here today. Thanks to Goldman for having us here to talk about Seres and what we think is going to be an incredibly important year for the company and for the microbiome space.

Before I start, I'll just note, we will be making forward-looking statements. So as usual, please refer to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot